Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial) (CAPTAF)
Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation - a Randomized Multicentre Study Comparing Atrial Fibrillation Ablation Strategy With Optimized Conventional Pharmacological Strategy After 12 Months Follow-up.
Sponsor: Swedish Heart Lung Foundation
This NA trial investigates Atrial Fibrillation and Quality of Life and is currently ongoing. Swedish Heart Lung Foundation leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Jun 2019 — Jan 2021 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Swedish Heart Lung Foundation
- Uppsala University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .